惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

Y
Y Combinator Blog
腾讯CDC
Recent Announcements
Recent Announcements
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
Hugging Face - Blog
Hugging Face - Blog
H
Help Net Security
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
Last Week in AI
Last Week in AI
博客园_首页
D
DataBreaches.Net
P
Proofpoint News Feed
云风的 BLOG
云风的 BLOG
V
Visual Studio Blog
月光博客
月光博客
Jina AI
Jina AI
Stack Overflow Blog
Stack Overflow Blog
酷 壳 – CoolShell
酷 壳 – CoolShell
博客园 - 【当耐特】
Vercel News
Vercel News
WordPress大学
WordPress大学
J
Java Code Geeks
博客园 - 聂微东
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
U
Unit 42

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
AptarGroup, Inc. (ATR) Q1 2026 Earnings Call Transcript
SA Transcripts · 2026-05-02 · via All Articles on Seeking Alpha

Q1: 2026-04-30 Earnings Summary

EPS of $1.19 beats by $0.04

 | 

Revenue of

$982.87M

(10.77% Y/Y)

beats by $26.92M

AptarGroup, Inc. (ATR) Q1 2026 Earnings Call May 1, 2026 9:00 AM EDT

Company Participants

Marry Skafidas - Senior Vice President of Investor Relations & Communications
Stephan Tanda - President, CEO & Executive Director
Gael Touya - President of Aptar Pharma
Vanessa Kanu - Executive VP & CFO

Conference Call Participants

Paul Knight - KeyBanc Capital Markets Inc., Research Division
Ghansham Panjabi - Robert W. Baird & Co. Incorporated, Research Division
George Staphos - BofA Securities, Research Division
Matthew Roberts - Raymond James & Associates, Inc., Research Division
Matthew Larew - William Blair & Company L.L.C., Research Division
Daniel Rizzo - Jefferies LLC, Research Division
Gabe Hajde - Wells Fargo Securities, LLC, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by, and welcome to Aptar's 2026 First Quarter Results Conference Call. [Operator Instructions] Introducing today's conference call is Mrs. Mary Skafidas, Senior Vice President, Investor Relations and Communications. Please go ahead.

Marry Skafidas
Senior Vice President of Investor Relations & Communications

Hello, everyone, and thanks for being with us today. Joining me on today's call are Stephan Tanda, our President and CEO; Vanessa Kanu, Executive Vice President and CFO; and Gael Touya, our CEO Designate and President of Aptar Pharma. Our press release and accompanying slide deck have been posted on our website under the Investor Relations page. During this call, we will be discussing certain non-GAAP financial measures. These measures are reconciled to the most directly comparable GAAP financial measure and the reconciliations are set forth in the press release. Please refer to the press release disseminated yesterday for the reconciliations of non-GAAP measures to the most comparable GAAP measure discussed during this earnings call. As always, we will post a replay of this call on our website. I would now like to turn the conference call over to Stephan.

Stephan Tanda